Ischemia-Modified Albumin

Ischemia-modified albumin is a proposed marker of myocardial ischaemia, in contrast to the necrosis markers that report cell death. It is based on the observation that the metal-binding capacity of serum albumin is reduced under ischaemic conditions, measured by the albumin cobalt-binding test.

Definition

Ischemia-modified albumin (IMA) refers to serum albumin whose N-terminal metal-binding site has reduced affinity for transition metals such as cobalt, a change attributed to ischaemic conditions; it is detected indirectly by the albumin cobalt-binding test, which measures unbound cobalt as a surrogate for the modified albumin.

Scope

This topic covers the biochemical basis of ischemia-modified albumin, the cobalt-binding assay used to detect it, its proposed position as an early ischaemia marker, and the specificity and standardisation limitations that have constrained its adoption. It treats IMA as a clinical-biochemistry analyte at an investigational level rather than as established diagnostic practice.

Core questions

• What biochemical change is IMA thought to represent?
• How does the albumin cobalt-binding test detect it?
• Why is IMA framed as an ischaemia marker rather than a necrosis marker?
• What limits the specificity and standardisation of IMA measurement?
• How does IMA relate conceptually to troponin in the marker hierarchy?

Key concepts

• Albumin N-terminal metal-binding site
• Reduced cobalt-binding capacity under ischaemia
• Albumin cobalt-binding (ACB) test
• Ischaemia marker versus necrosis marker
• Early-rise kinetics
• Specificity and confounding (non-cardiac ischaemia, albumin variation)
• Assay standardisation limitations

Mechanisms

The N-terminus of human serum albumin binds transition metal ions such as cobalt, copper, and nickel. The ischemia-modified albumin hypothesis proposes that conditions accompanying ischaemia — including acidosis, free-radical exposure, and altered metal handling — modify this N-terminal site so that albumin binds cobalt less avidly. The albumin cobalt-binding test exploits this by adding cobalt to serum and measuring the cobalt that remains unbound: more unbound cobalt is interpreted as more modified albumin. Because the modification is proposed to occur during ischaemia rather than after cell death, IMA is positioned conceptually as an early ischaemia marker, potentially rising before necrosis markers. However, the change is not specific to myocardial ischaemia, depends on serum albumin concentration, and has faced assay-standardisation difficulties, which together have limited its clinical-biochemistry role.

Clinical relevance

Ischemia-modified albumin is an investigational marker whose appeal lies in reporting ischaemia rather than necrosis, but specificity and standardisation limitations have kept it from the central role held by troponin. This entry describes its biochemistry as evidence; it does not provide diagnostic thresholds or treatment guidance for individual patients.

Evidence & guidelines

The original description of the cobalt-albumin binding assay (Bar-Or et al., 2000) introduced IMA as a potential ischaemia marker, but consensus frameworks such as the Fourth Universal Definition of Myocardial Infarction (Thygesen et al., 2018) and reference-limit work for established markers (Apple et al., 2003) continue to centre troponin, and IMA is not adopted as a standard cardiac biomarker in these documents.

History

The albumin cobalt-binding test was described around 2000 as a way to detect a proposed ischaemia-related modification of albumin, generating interest in an early marker that could precede necrosis. Subsequent evaluation highlighted limited specificity for cardiac ischaemia and dependence on albumin concentration and assay conditions, which constrained its uptake relative to troponin.

Debates

Is IMA specific enough to be a useful cardiac marker?

Because the proposed albumin modification is not unique to myocardial ischaemia and the assay depends on serum albumin levels and standardisation, whether IMA adds value beyond established markers has remained unresolved, and it has not entered routine consensus frameworks.

Key figures

• David Bar-Or

Seminal works

• bar-or-2000

Frequently asked questions

How is ischemia-modified albumin different from troponin?

Troponin is released when heart-muscle cells die, so it marks necrosis, whereas ischemia-modified albumin is proposed to form during ischaemia itself, before cell death; this is its conceptual appeal, but its lack of specificity for cardiac ischaemia has limited its practical role.

How is ischemia-modified albumin measured?

It is measured indirectly by the albumin cobalt-binding test: cobalt is added to a serum sample, and the amount of cobalt that albumin fails to bind is taken as a surrogate for the modified, lower-affinity albumin attributed to ischaemia.